In collaboration with neurologists, endocrinologists, other physicians, and basic scientists, the Columbia Neuropathy Research Center is committed to basic and human research designed to improve our understanding and effective treatment of peripheral and autonomic neuropathies of all types.
The CNRC is funded exclusively by donor support and research grants.
A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects with Charcot Marie Tooth disease
A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy.
A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects with Painful Diabetic Peripheral Neuropathy
This is a Phase III study of the experimental drug VM202. VM202 is a DNA plasmid encoding human hepatocyte growth factor (HGF). HGF is known to be a potent angiogenic and potentially neurogenic agent. In phase I and II studies, a single treatment of intramuscular injections of VM202 into the calves of patients with painful DPN resulted in significant reductions in pain at 3 and 6 months, as well as improvements in monofilament testing.
In this study, patients will receive 2 treatments of either VM202 or placebo at baseline and 2 months; randomization will be 2:1 to VM202 or placebo. The study will be 9 months long and include 477 patients.
Click here for additional information
For more information and to see if you qualify, please call:
The Columbia Neuropathy Research Center
The Neurological Institute
710 West 168th Street, 2nd floor
New York, NY 10032